Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Quentin Anstee.

Newcastle AuthorsTitleYearFull text
Dr Rebecca Darlay
Professor Heather Cordell
Professor Quentin Anstee
Professor Ann Daly
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation2022
Professor Quentin Anstee
An international survey on patterns of practice in NAFLD and expectations for therapies—The POP-NEXT project2022
Tim Hicks
Dr Will Jones
Dr Jana Suklan
Professor Quentin Anstee
Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study2022
Dr Dina Tiniakos
Professor Quentin Anstee
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD2022
Professor Quentin Anstee
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)2022
Professor Quentin Anstee
Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis2022
Helen Jarvis
Hannah O'Keefe
Professor Dawn Craig
Dr Daniel Stow
Professor Barbara Hanratty
et al.
Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis2022
Professor Quentin Anstee
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study2022
Dr Katherine Johnson
Dr Peter Leary
Dr Olivier Govaere
Dr Matthew Barter
Sarah Charlton
et al.
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance2022
Dr Marie Boyle
Dr Stuart McPherson
Professor Arun Sanyal
Professor Quentin Anstee
Letter: non-invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply2022
Professor Arun Sanyal
Professor Quentin Anstee
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis2022
Dr Olivier Govaere
Dr Rebecca Darlay
Dr Julien Peltier
Dr Jeremy Palmer
Dr Massimo Younes
et al.
Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease2022
Dr Olivier Govaere
Professor Ann Daly
Professor Quentin Anstee
Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease2022
Professor Quentin Anstee
Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles2022
Dr Paula Iruzubieta
Professor Quentin Anstee
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles2022
Professor Quentin Anstee
Professor Arun Sanyal
Noninvasive Evaluation of Response to Obeticholic Acid in Patients with NASH: Results from the REGENERATE Study2022
Professor Quentin Anstee
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials2022
Dr Sam Tingle
Dr Emily Thompson
Lucy Bates
Dr Ibrahim Ibrahim
Dr Olivier Govaere
et al.
Pharmacological testing of therapeutics using normothermic machine perfusion: A pilot study of 2,4-dinitrophenol delivery to steatotic human livers2022
Jadine Scragg
Dr Sarah Charman
Dr Vincent van Hees
Dr Leah Avery
Dr Guy Taylor
et al.
Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease2022
Dr Stuart McPherson
Professor Quentin Anstee
Dr Kate Hallsworth
Helen Jarvis
Dr Dina Mansour
et al.
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group2022
Dr Olivier Govaere
Professor Quentin Anstee
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease2022
Professor Quentin Anstee
Dr Kate Hallsworth
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions2022
Professor Quentin Anstee
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score2022
Laura Haigh
Colette Kirk
Dr Jenny Gallacher
Linda Errington
Professor John Mathers
et al.
The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis2022
Professor Quentin Anstee
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH2021
Professor Quentin Anstee
A molecular signature for the metabolic syndrome by urine metabolomics2021
Nardeen Eldafashi
Dr Rebecca Darlay
Dr Ruchi Shukla
Misti McCain
Robyn Watson
et al.
A pdcd1 role in the genetic predisposition to nafld-hcc?2021
Professor Quentin Anstee
A Randomized Controlled Trial of the PanPPAR Agonist Lanifibranor in NASH2021
Professor Quentin Anstee
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis2021
Dr Massimo Younes
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Alastair Burt
Marco Zaki
et al.
Caucasian Lean Subjects with Non-Alcoholic Fatty Liver Disease Share Long-Term Prognosis of Non-Lean: Time for Reappraisal of BMI-Driven Approach?2021
Professor Arun Sanyal
Professor Quentin Anstee
Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis2021
Professor Quentin Anstee
Professor Arun Sanyal
Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study2021
Professor Quentin Anstee
Diagnostic Accuracy of Elastography and Magnetic Resonance Imaging in Patients with NAFLD: a systematic review and meta-analysis2021
Dr Massimo Younes
Shilpa Aggarwal
Dr Himanshu Garg
Professor Quentin Anstee
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD – An individual patient data meta-analysis2021
Professor Quentin Anstee
Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review2021
Dr Kate Hallsworth
Dr Stuart McPherson
Professor Quentin Anstee
Laura Haigh
Dr Leah Avery
et al.
Digital Intervention with Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults with Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping2021
Dr Dina Mansour
Professor Quentin Anstee
Dr Stuart McPherson
Embedding assessment of liver fibrosis into routine diabetic review in primary care2021
Jadine Scragg
Dr Kate Hallsworth
Guy Taylor
Dr Sophie Cassidy
Laura Haigh
et al.
Factors associated with engagement and adherence to a low energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease2021
Dr Laura Neilson
Dr Louise MacDougall
Dr Timothy Hardy
Dr David Beaton
Dr April Phaw
et al.
Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease2021
Marco Zaki
Dr Ahmed Mahdi
Dr Gillian Patman
Anna Whitehead
Joao Mauricio
et al.
Key features of the environment promoting liver cancer in the absence of cirrhosis2021
Dr Jack Leslie
Dr Emma Scott
Professor Quentin Anstee
Professor Fiona Oakley
Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma 2021
Dr Massimo Younes
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Alastair Burt
Marco Youssef William Zaki
et al.
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease2021
Professor Quentin Anstee
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests2021
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Pierre Bedossa
Dr Simon Cockell
Dr Massimo Younes
et al.
NASH limits anti-tumor surveillance in immunotherapy-treated HCC2021
Dr Luca Miele
Professor Quentin Anstee
Professor Helen Reeves
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores2021
Professor Ann Daly
Dr Olivier Govaere
Professor Quentin Anstee
Peptide-Based Urinary Monitoring of Fibrotic Non-Alcoholic Steatohepatitis by Mass Barcoded Activity-Based Sensors2021
Professor Quentin Anstee
Prognostic accuracy of FIB-4, NAFLD fibrosis score, and APRI for NAFLD-related events: a systematic review2021
Professor Quentin Anstee
Priyadarshini Basu
Dr Pallav Bhatnagar
Professor Ann Daly
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis2021
Professor Quentin Anstee
Systematic review with meta-analyses: Diagnostic accuracy of fibrometer tests in patients with non-alcoholic fatty liver disease2021
Professor Quentin Anstee
Systematic review with meta-analysis: Diagnostic accuracy of Pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease2021
Professor Quentin Anstee
The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis2021
Professor Quentin Anstee
The European ‘NAFLD Preparedness Index’ — is Europe ready to meet the challenge of fatty liver disease?2021
Dr John Lazarus
Professor Quentin Anstee
The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?2021
Helen Jarvis
Dr Stuart McPherson
Professor Quentin Anstee
Professor Barbara Hanratty
The pathway to better primary care for chronic liver disease2021
Dr Olivier Govaere
Dr Simon Cockell
Professor Ann Daly
Professor Quentin Anstee
Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis2021
Professor Pierre Bedossa
Professor Quentin Anstee
Professor Arun Sanyal
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study2020
Professor Quentin Anstee
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe2020
Professor Arun Sanyal
Professor Quentin Anstee
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial2020
Professor Quentin Anstee
Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis2020
Dr Batoul Nasr
Professor Quentin Anstee
Dr Stuart McPherson
Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis2020
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Quentin Anstee
Professor Fiona Oakley
Bone Morphogenic Protein 8B Promotes the Progression of Non-Alcoholic Steatohepatitis2020
Professor Quentin Anstee
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design2020
Professor Quentin Anstee
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis2020
Dr Olivier Govaere
Professor Quentin Anstee
Erratum: Adverse effects of PD-1 targeted immunotherapy in NAFLD-triggered HCC2020
Dr Matthew Breckons
Dr Yemi Oluboyede
Professor Luke Vale
Dr Laura Ternent
Professor Arun Sanyal
et al.
Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis2020
Professor Quentin Anstee
Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes2020
Jadine Scragg
Dr Leah Avery
Dr Sophie Cassidy
Dr Guy Taylor
Laura Haigh
et al.
Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with non-alcoholic fatty liver disease2020
Professor Quentin Anstee
Professor Pierre Bedossa
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study2020
Professor Quentin Anstee
Dr Rebecca Darlay
Dr Simon Cockell
Dr Olivier Govaere
Dr Dina Tiniakos
et al.
Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort2020
Dr Lorraine McSweeney
Dr Matthew Breckons
Dr Gulnar Fattakhova
Professor Luke Vale
Dr Laura Ternent
et al.
Health-Related Quality of Life and Patient-Reported Outcome Measures in NASH-related Cirrhosis2020
Dr Olivier Govaere
Professor Quentin Anstee
Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers2020
Helen Jarvis
Professor Dawn Craig
Dr Robert Barker
Dr Gemma Frances Spiers
Dr Daniel Stow
et al.
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population based observational studies2020
Helen Jarvis
Hannah O'Keefe
Professor Dawn Craig
Dr Daniel Stow
Professor Quentin Anstee
et al.
People with NAFLD also drink alcohol - how should we advise and manage this expanding group in primary care? A systematic review.2020
Dr Massimo Younes
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Alastair Burt
Marco Zaki
et al.
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease2020
Dr Massimo Younes
Dr Olivier Govaere
Dr Luca Miele
Dr Dina Tiniakos
Professor Alastair Burt
et al.
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease2020
Dr Dina Tiniakos
Susan Harrison
Professor Quentin Anstee
qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients with Non-Alcoholic Steatohepatitis2020
Professor Quentin Anstee
Reply to: “Caveats for the implementation of global strategies against non-alcoholic fatty liver disease”2020
Professor Quentin Anstee
Reply to: “Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease”2020
Professor Quentin Anstee
Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results from the STELLAR Phase 3 Trials2020
Professor Quentin Anstee
The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: the GAIN Study2020
Dr Timothy Hardy
Kristy Wonders
Dr Massimo Younes
Professor Pierre Bedossa
Entesar Betelmal
et al.
The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease2020
Professor Quentin Anstee
The times they are a-changin' (for NAFLD as well)2020
Dr Olivier Govaere
Dr Simon Cockell
Dr Dina Tiniakos
Dr Rachel Queen
Dr Massimo Younes
et al.
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis2020
Professor Quentin Anstee
Professor Pierre Bedossa
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease2019
Laura Haigh
Dr Dave Houghton
Elsbeth Henderson
Dr Leah Avery
Dr Timothy Hardy
et al.
Barriers and Facilitators to Mediterranean Diet Adoption by Patients with Non-alcoholic Fatty Liver Disease in Northern Europe.2019
Professor Quentin Anstee
Dr David Price
Dr Brendan Payne
Central obesity and non-alcoholic fatty liver disease in people living with HIV: a case for targeted screening?2019
Dr Federico Ravaioli
Professor Quentin Anstee
Editorial: collagen proportionate area as a prognostic indicator in NAFLD2019
Professor Quentin Anstee
Professor Helen Reeves
Dr Olivier Govaere
From NASH to HCC: current concepts and future challenges2019
Dr Marie Boyle
Kate Hallsworth
Dr Dina Tiniakos
Professor Quentin Anstee
Health-related Quality of Life in Non-alcoholic Fatty Liver Disease Associates With Hepatic Inflammation.2019
Professor Quentin Anstee
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials2019
Professor Quentin Anstee
Professor Pierre Bedossa
Professor Arun Sanyal
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial2019
Dr Marie Boyle
Dr Dina Tiniakos
Dr Olivier Govaere
Dr Massimo Younes
Dr Stuart McPherson
et al.
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease2019
Professor Arun Sanyal
Professor Quentin Anstee
Professor Pierre Bedossa
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis2019
Professor Arun Sanyal
Professor Quentin Anstee
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD2019
Dr Dave Houghton
Dr Kate Hallsworth
Dr Sophie Cassidy
Christian Thoma
Dr Leah Avery
et al.
The degree of hepatic steatosis associates with impaired cardiac and autonomic function2019
Dr Kate Hallsworth
Dr Stephan Dombrowski
Dr Stuart McPherson
Professor Quentin Anstee
Dr Leah Avery
et al.
Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study2019
Professor Loranne Agius
Professor Quentin Anstee
Application of long single-stranded DNA donors in genome editing: Generation and validation of mouse mutants2018
Professor Loranne Agius
Professor Quentin Anstee
Application of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants2018
Dr John Brain
Professor Alastair Burt
Professor Quentin Anstee
Author correction: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity2018
Professor Quentin Anstee
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science2018
Dr Marie Boyle
Professor Quentin Anstee
Editorial: hepatocellular carcinoma in non-cirrhotic NASH - a troubling reality2018
Dr John Brain
Professor Quentin Anstee
Erratum to: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity (Nature, (2017), 551, 7680, (340-345), 10.1038/nature24302)2018
Professor Quentin Anstee
European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale.2018
Dr Dina Tiniakos
Professor Quentin Anstee
Professor Alastair Burt
Fatty Liver Disease2018
Emma Scott
Professor Quentin Anstee
Genetics of alcoholic liver disease and non-alcoholic steatohepatitis2018
Professor Quentin Anstee
Dr Timothy Hardy
Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention2018
Professor Quentin Anstee
Professor Chris Day
Professor Arun Sanyal
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-20302018
Professor Quentin Anstee
Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis2018
Professor Quentin Anstee
Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany2018
Professor Quentin Anstee
Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study2018
Professor Quentin Anstee
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease2018
Dr Marie Boyle
Dr Steven Masson
Professor Quentin Anstee
The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease2018
Dr Emma Scott
Professor Quentin Anstee
The genetics of alcoholic liver disease and non-alcoholic steatohepatitis2018
Dr Olivier Govaere
Professor Quentin Anstee
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis2018
Professor Quentin Anstee
Thrombin and factor Xa link the coagulation system with liver fibrosis2018
Dr Stuart McPherson
Dr Nina Wilson
Dr Dina Tiniakos
Dr Jennifer Wilkinson
Professor Alastair Burt
et al.
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis2017
Dr Stuart McPherson
Dr Timothy Hardy
Dr Dina Tiniakos
Professor Alastair Burt
Professor Chris Day
et al.
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis2017
Dr Dave Houghton
Dr Sophie Cassidy
Dr Christian Thoma
Dr Kate Hallsworth
Dr Leah Avery
et al.
Autonomic function is impaired across the spectrum of NAFLD2017
Professor Quentin Anstee
Professor Arun Sanyal
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum2017
Dr David Sheridan
Professor Quentin Anstee
Dr Stuart McPherson
Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey2017
Dr Mikolaj Ogrodnik
Dr Satomi Miwa
Dr Dina Tiniakos
Dr Caroline Wilson
Professor Chris Day
et al.
Cellular senescence drives age-dependent hepatic steatosis2017
Dr Dave Houghton
Dr Kate Hallsworth
Dr Christian Thoma
Dr Sophie Cassidy
Dr Timothy Hardy
et al.
Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers2017
Dr Dave Houghton
Christian Thoma
Dr Kate Hallsworth
Dr Sophie Cassidy
Dr Timothy Hardy
et al.
Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial2017
Professor Quentin Anstee
Genetic variation in GABRβ1 and the risk for developing alcohol dependence2017
Dr Emma Scott
Dr Jeremy Palmer
Professor Quentin Anstee
Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD2017
Dr John Brain
Professor Alastair Burt
Professor Quentin Anstee
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity2017
Dr Leah Avery
Professor Catherine Exley
Dr Stuart McPherson
Professor Mike Trenell
Professor Quentin Anstee
et al.
Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice2017
Misti McCain
Dr Luca Miele
Dr Paula Iruzubieta
Professor Helen Reeves
Professor Quentin Anstee
et al.
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals2017
Professor Quentin Anstee
NAFLD: PNPLA3 and obesity: a synergistic relationship in NAFLD2017
Professor Quentin Anstee
Non-Alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases2017
Dr Timothy Hardy
Dr Mujdat Zeybel
Professor Chris Day
Dr Christian Dipper
Dr Steven Masson
et al.
Plasma DNA methylation: A potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease2017
Dr Lucy Walker
Professor Ann Daly
Dr Luca Miele
Professor Quentin Anstee
Professor Helen Reeves
et al.
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease2017
Dr Olivier Govaere
Professor Quentin Anstee
The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma2017
Professor Quentin Anstee
Dr Yang-Lin Liu
Dr Rebecca Darlay
Professor Heather Cordell
Professor Ann Daly
et al.
Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans2017
Professor Quentin Anstee
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study2017
Professor Quentin Anstee
A fatty liver leads to a broken heart?2016
Professor Quentin Anstee
Professor Arun Sanyal
ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial2016
Dr Stuart McPherson
Professor Quentin Anstee
Changing Epidemiology of Chronic Liver Disease Among Ethnic Groups in the United States2016
Dr Dina Tiniakos
Professor Quentin Anstee
Professor Chris Day
Professor Alastair Burt
Dr John Brain
et al.
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference2016
Professor Quentin Anstee
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening2016
Dr Dave Houghton
Dr Sophie Cassidy
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Professor Roy Taylor
et al.
Exercise reduces liver fat and improves body composition but not insulin sensitivity or inflammatory markers in non-alcoholic steatohepatitis2016
Professor Quentin Anstee
Professor Chris Day
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease2016
Dr Nimantha de Alwis
Professor Quentin Anstee
Professor Chris Day
How to Diagnose Nonalcoholic Fatty Liver Disease2016
Professor Quentin Anstee
Professor Arun Sanyal
Improvement in NASH histological activity highly correlates with fibrosis regression2016
Dr Timothy Hardy
Professor Fiona Oakley
Professor Quentin Anstee
Professor Chris Day
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum2016
Professor Quentin Anstee
Novel Fibroscan-Based Score to Diagnose NASH and its severity in A Multi-centre UK Cohort of Patients with Suspected NAFLD2016
Professor Quentin Anstee
Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis2016
Professor Quentin Anstee
Dr David Sheridan
Staging fibrosis and excluding advanced fibrosis in patients with NAFLD: comparison of non-invasive markers in an interim analysis from a prospective multicentre study2016
Professor Quentin Anstee
Professor Arun Sanyal
Validation of mir-34a, mir-122 and mir-200a as bio-markers for identification of NASH patients eligible for treatment2016
Professor Quentin Anstee
An overview of the genetics, mechanisms and management of NAFLD and ALD2015
Professor Quentin Anstee
An overview of the genetics, mechanisms and management of NAFLD and ALD2015
Dr Mujdat Zeybel
Dr Timothy Hardy
Stuart Robinson
Christopher Fox
Professor Quentin Anstee
et al.
Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease2015
Anna Whitehead
Dr Gillian Patman
Professor Chris Day
Dr Dina Tiniakos
Professor Quentin Anstee
et al.
Effects of FXR agonist PX20606 on tumour formation in animal models of non-alcoholic fatty liver disease2015
Dr Stuart McPherson
Dr Timothy Hardy
Elsbeth Henderson
Professor Alastair Burt
Professor Chris Day
et al.
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management2015
Dr Dave Houghton
Dr Christian Thoma
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Professor Chris Day
et al.
Exercise reduces liver fat, visceral fat and circulating triglycerides, but not circulating inflammatory markers in non-alcoholic steatohepatitis2015
Professor Quentin Anstee
Professor Ann Daly
Professor Chris Day
Genetics of Alcoholic Liver Disease2015
Dr Stuart McPherson
Dr Timothy Hardy
Professor Alastair Burt
Professor Chris Day
Professor Quentin Anstee
et al.
High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (>=65 years) with NAFLD2015
Dr Timothy Hardy
Victoria Sharkey
Dr Mujdat Zeybel
Professor John Mathers
Steven White
et al.
Laser capture microdissection reveals cell-specific DNA methylation signatures in key fibrosis modifier genes in chronic liver disease2015
Dr Jeremy Palmer
Dr Yang-Lin Liu
Professor Chris Day
Professor Ann Daly
Professor Quentin Anstee
et al.
Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress2015
Dr Kate Hallsworth
Christian Thoma
Dr Kieren Hollingsworth
Dr Sophie Cassidy
Professor Quentin Anstee
et al.
Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomised controlled trial2015
Dr Jess Dyson
Professor Quentin Anstee
Dr Stuart McPherson
Non-alcoholic fatty liver disease: a practical approach to treatment2015
Professor Chris Day
Professor Quentin Anstee
Nonalcoholic Fatty Liver Disease: Foreword2015
Dr Timothy Hardy
Professor Quentin Anstee
Professor Chris Day
Nonalcoholic fatty liver disease: new treatments2015
Anna Whitehead
Laura Ogle
Dr Gillian Patman
Dr Ali Anwar
Dr Dina Tiniakos
et al.
Ras and p-ERK in metabolic syndrome associated Hepatocellular Carcinoma (HCC)2015
Professor Quentin Anstee
Dr Yang-Lin Liu
Professor Chris Day
Professor Helen Reeves
Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance2015
Professor Helen Reeves
Dr Luca Miele
Professor Quentin Anstee
Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash2015
Rodolphe Anty
Professor Chris Day
Professor Ann Daly
Anh Tran
Professor Quentin Anstee
et al.
The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD2015
Professor Quentin Anstee
Professor Chris Day
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF22015
Professor Quentin Anstee
The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity2015
Professor Ann Daly
Professor Chris Day
Dr Yang-Lin Liu
Professor Quentin Anstee
TM6SF2 as a Genetic Risk Factor for Fibrosis2015
Dr Yang-Lin Liu
Professor Ann Daly
Professor Chris Day
Professor Quentin Anstee
TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?2015
Professor Quentin Anstee
Professor Chris Day
Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis2015
Dr Stuart McPherson
Professor Quentin Anstee
Wafarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year2015
Dr Yang-Lin Liu
Dr Gillian Patman
Julian Leathart
Professor Alastair Burt
Professor Chris Day
et al.
Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma2014
Dr Mujdat Zeybel
Dr Timothy Hardy
Christopher Fox
Dr Steven Masson
Professor Derek Mann
et al.
Differential DNA methylation of genes involved in fibrosis progression in NAFLD and ALD2014
Julian Leathart
Professor Ann Daly
Professor Chris Day
Professor Quentin Anstee
Gene Polymorphisms of Cellular Senescence Marker P21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease2014
Professor Quentin Anstee
Liver and Biliary Tract Disease2014
Rodolphe Anty
Professor Quentin Anstee
Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients2014
Dr Stuart McPherson
Elsbeth Henderson
Dr Timothy Hardy
Professor Alastair Burt
Professor Chris Day
et al.
Natural history of NAFLD: A study of 108 patients with paired liver biopsies2014
Dr Stuart McPherson
Dr Timothy Hardy
Professor Alastair Burt
Professor Chris Day
Professor Quentin Anstee
et al.
Natural History of NAFLD: A Study of 108 Patients with Paired Liver Biopsies2014
Dr Kate Hallsworth
Dr Christian Thoma
Sarah Moore
Dr Thomas Ploetz
Professor Quentin Anstee
et al.
Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls2014
Dr Jess Dyson
Dr Stuart McPherson
Professor Quentin Anstee
Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification2014
Rodolphe Anty
Professor Quentin Anstee
Prophylaxis of bacterial infections in cirrhosis: Is an optimal 25-OH vitamin D level required?2014
Professor Quentin Anstee
Dr Mark Hudson
Professor Helen Reeves
Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area"2014
Dr Stuart McPherson
Elsbeth Henderson
Professor Alastair Burt
Professor Chris Day
Professor Quentin Anstee
et al.
Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease2014
Dr Yang-Lin Liu
Professor Helen Reeves
Professor Alastair Burt
Dr Dina Tiniakos
Dr Stuart McPherson
et al.
TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease2014
Professor Quentin Anstee
Dr Rebecca Darlay
Julian Leathart
Yilei Liu
Professor Alastair Burt
et al.
A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease2013
Anna Whitehead
Dr Gillian Patman
Liam Cornell
Dr Despina Televantou
Professor Nicola Curtin
et al.
A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?2013
Dr Stuart McPherson
Professor Quentin Anstee
Professor Chris Day
Professor Alastair Burt
Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?2013
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Dr Christian Thoma
Professor Djordje Jakovljevic
Dr Guy MacGowan
et al.
Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease2013
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Dr Christian Thoma
Professor Djordje Jakovljevic
Dr Guy MacGowan
et al.
Cardiac function improves following high intensity intermittent exercise in adults with non-alcoholic fatty liver disease2013
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Dr Christian Thoma
Professor Quentin Anstee
Professor Chris Day
et al.
Cardiac Function Improves Following High Intensity Intermittent Exercise Therapy in Non-Alcoholic Fatty Liver Disease2013
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Dr Christian Thoma
Professor Djordje Jakovljevic
Dr Guy MacGowan
et al.
Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease2013
Dr Yang-Lin LIU
Dr Gillian Patman
Julian Leathart
Professor Alastair Burt
Professor Chris Day
et al.
Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma2013
Professor Quentin Anstee
Dr Steven Masson
Dr Stuart McPherson
Does the Pre-Bone Mineral Density Frax Score Predict Fracture Risk in Patients with Cirrhosis?2013
Professor Quentin Anstee
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment2013
Dr Kate Hallsworth
Dr Christian Thoma
Professor Quentin Anstee
Professor Chris Day
Professor Mike Trenell
et al.
Higher Objectively Measured Sedentary Behaviour and Lower Levels of Physical Activity than Matched Healthy Controls2013
Dr Christian Thoma
Dr Kate Hallsworth
Dr Kieren Hollingsworth
Professor Quentin Anstee
Professor Chris Day
et al.
HIGH-INTENSITY INTERMITTENT EXERCISE THERAPY REDUCES LIVER FAT AND IMPROVES BODY COMPOSITION IN ADULTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE2013
Professor Quentin Anstee
Dr Yang-Lin Liu
Professor Heather Cordell
Dr Rebecca Darlay
Professor Chris Day
et al.
Mapping Expression Quantitative Traits Loci (EQTL) for PNPLA3 Gene Identifies Additional SNPs Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of rs7384092013
Dr Gillian Patman
Dr Despina Televantou
Anna Whitehead
Professor Chris Day
Professor Fiona Oakley
et al.
Mild Steatosis and Impaired Glucose Tolerance are Associated with Liver Cancer Development, While Progression to Nash Increases Number/Size in an Animal Model of NAFLD2013
Professor Quentin Anstee
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice2013
Professor Quentin Anstee
Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition2013
Dr Jess Dyson
Dr Stuart McPherson
Professor Quentin Anstee
Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification2013
Professor Quentin Anstee
Professor Chris Day
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis2013
Professor Quentin Anstee
Rifaximin in Non-Alcoholic Steatohepatitis an Open-Label Pilot Study2013
Professor Quentin Anstee
Rifaximin in Non-Alcoholic Steatohepatitis: An Open-Label Pilot Study2013
Professor Quentin Anstee
Professor Chris Day
The genetics of NAFLD2013
Professor Quentin Anstee
Professor Chris Day
S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility2012
Professor Quentin Anstee
Professor Chris Day
A lipid to treat non-alcoholic fatty liver disease – The dawn of ‘lipo-rehabilitation’?2012
Professor Quentin Anstee
A role for anticoagulation in fibrogenesis: Supression of human hepatic stellate cell contractility and liver fibrosis in vitro and vivo2012
Professor Quentin Anstee
Dr Rebecca Darlay
Julian Leathart
Professor Helen Reeves
Professor Alastair Burt
et al.
Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD2012
Professor Quentin Anstee
H-1-NMR metabolic profiling in germ-free and conventionally housed mouse models of acetaminophen-induced hepatotoxicity2012
Dr Gillian Patman
Douglas Hui
Professor Quentin Anstee
Professor Helen Reeves
Kruppel-like factor 6 splice variant 3 (KLF6-SV3) - The redox sensitive splice variant of KLF6 expressed in non-alcoholic steatohepatitis (NASH)2012
Professor Quentin Anstee
Measuring the effectiveness of a multidisciplinary non-alcoholic fatty liver disease clinic2012
Dr Mujdat Zeybel
Dr Timothy Hardy
Frances Wong
Professor John Mathers
Christopher Fox
et al.
Multigenerational epigenetic adaptation of the hepatic wound-healing response2012
Dr Gillian Patman
Douglas Hui
Professor Quentin Anstee
Professor Helen Reeves
Oxidative stress induces alternative splicing and nuclear translocation of kruppel like factor 62012
Professor Quentin Anstee
Quantifying hepatic steatosis - more than meets the eye2012
Professor Quentin Anstee
Targeted inhibition of tissue factor and thrombin on CD31 expressing cells suppresses hepatic fibrosis in CCl4 treated mice2012
Professor Quentin Anstee
Targeted inhibition of tissue factor and thrombin on CD31 expressing cells supresses hepatic fibrosis in CCL4 treated mice2012
Professor Quentin Anstee
Targeted inhibition of Tissue Factor suppresses hepatic fibrosis in CCL4 treated mice2012
Ahmad Alserri
Professor Quentin Anstee
Julian Leathart
Julia Patch
Professor Chris Day
et al.
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies2012
Dr Stuart McPherson
Dr Timothy Hardy
Professor Alastair Burt
Professor Chris Day
Professor Quentin Anstee
et al.
The FIB-4 score reliability excludes advanced fibrosis in a diabetic cohort with NAFLD2012
Professor Quentin Anstee
A novel mouse model of hepatic glycogen storage disease Type 3 identified using a phenotype-driven ethyl-nitrosourea (ENU) mutagensis screen2011
Professor Quentin Anstee
Activating Autophagocytosis Decreases Fat Within the Liver2011
Professor Quentin Anstee
Animal models in nonalcoholic steatohepatitis research: utility and clinical translation2011
Dr Stuart McPherson
Professor Quentin Anstee
Elsbeth Henderson
Professor Alastair Burt
Professor Chris Day
et al.
Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?2011
Professor Quentin Anstee
Professor Ann Daly
Professor Chris Day
Genetic modifiers of non-alcoholic fatty liver disease progression2011
Professor Quentin Anstee
Professor Ann Daly
Professor Chris Day
Genetics of alcoholic liver disease and nonalcoholic fatty liver disease2011
Dr Gillian Patman
Professor Quentin Anstee
Professor Helen Reeves
Hepatocellular Carcinoma in NASH: Is there a biological Rationale?2011
Professor Quentin Anstee
Dr Stuart McPherson
Professor Chris Day
How big a problem is non-alcoholic fatty liver disease?2011
Professor Quentin Anstee
Hypercoagulability in cirrhosis: causes and consequences2011
Professor Quentin Anstee
Multi-Excitation Fluorescence Spectroscopy for Analysis of Non-Alcoholic Fatty Liver Disease2011
Professor Quentin Anstee
The role of hypercoagulability in liver fibrogenesis2011
Professor Quentin Anstee
Vanin-1 activity modulates the steatosis-steatohepatitis transition in progressive non-alcoholic steatohepatitis2011
Professor Quentin Anstee
Cell surface pantetheinase, Vanin-1, increases oxidative damage in acetaminophen-induced liver injury via a reduction in glutathione2010
Professor Quentin Anstee
Coagulation proteins in acute liver injury: a role in initiation and propagation2010
Professor Quentin Anstee
Brian Smith
Hepatitis B and hepatitis C co-infection2010
Professor Quentin Anstee
Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis2010
Professor Quentin Anstee
Is oil red-O and digital image analysis the gold standard for quantifying steatosis in the liver?2010
Professor Quentin Anstee
Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?2010
Professor Quentin Anstee
Novel quantitative trait locus for acetaminophen-induced hepatotoxicty identified on chromosome 182010
Professor Quentin Anstee
Rational Testing: Investigating mildly abnormal serum aminotransferase values2010
Professor Quentin Anstee
Role of monocytes and macrophages in experimental and human acute liver failure2010
Professor Quentin Anstee
A missense mutation in the non-neural G-protein α-subunit isoforms modulates susceptibility to obesity2009
Professor Quentin Anstee
Autofluorescence: modelling a tool for assessment of steatotic marginal grafts in liver transplantation2009
Professor Quentin Anstee
Professor Matthew Wright
Parenchymal extinction: coagulation and hepatic fibrogenesis2009
Professor Quentin Anstee
Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue2009
Professor Quentin Anstee
The importance of fatty liver disease in clinical practice2009
Professor Quentin Anstee
Professor Matthew Wright
Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies2008
Professor Quentin Anstee
Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis2008
Professor Quentin Anstee
Hypercoagulation and thrombophilia in liver disease2008
Professor Quentin Anstee
Identification of a model of alcohol preference and its similarity to human alcoholism2008
Professor Quentin Anstee
Can disease progression in non-alcoholic fatty liver disease be predicted by metabolic biomarkers of lipid accumulation and peroxidation?2007
Professor Quentin Anstee
Dietary constituents in mice are reflected in the hepatic lipid profile as detected by carbon-13 magic angle spinning magnetic resonance spectroscopy2007
Professor Quentin Anstee
Microarray analysis demonstrates insulin resistance is central to NASH pathogenesis in the IGT/6 model and suggests a role for CEACAM-1 in disease pathogenesis2007
Professor Quentin Anstee
Microarray principal components analysis demonstrates expression of Vanin-1 is a strong determinant of NASH pathogenesis in the IGT/6 model2006
Professor Quentin Anstee
Mouse models in non-alcoholic fatty liver disease and steatohepatitis research2006
Professor Quentin Anstee
Professor Matthew Wright
The factor V Leiden mutation accelerates disease progression in a mouse model of hepatic fibrosis induced by chronic carbon tetrachloride exposure2004
Professor Quentin Anstee
A novel murine model of non-alcoholic steatohepatitis generated using a sensitised ENU mutagenesis screen2003
Professor Quentin Anstee
The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease2000
Professor Quentin Anstee
[Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease1999
Professor Quentin Anstee
[Abstract] Safety of percutaneous gastrostomy (PEG) feeding in Crohn's disease1999
Professor Quentin Anstee
Vectorial function of major histocompatibility complex class II in a human intestinal cell line1999